Landmark Ruling in Detransition Case

A jury in Westchester County has awarded $2 million to 22-year-old Fox Varian, marking a significant moment in U.S. legal history regarding “detransitioner” cases. This case is notable as it’s the first of its kind to reach a jury trial, resulting in a win for the plaintiff.

Varian, originally a biological female, dealt with gender dysphoria during her teenage years and identified as a transgender male, undergoing both social and medical transitions. Over time, though, she decided to discontinue her transition and returned to identifying with her biological sex, as her mental health showed signs of improvement.

She briefly went by the name Rowan during this period.

According to various court reports, Varian detransitioned approximately three years after undergoing a double mastectomy, known informally as “top surgery,” at the age of 19. After experiencing regret and reassessing her gender identity, she reverted to identifying as female well before initiating her lawsuit in 2023.

In a verdict announced on Friday, a six-person jury determined that both psychologist Dr. Kenneth Einhorn and plastic surgeon Dr. Simon H. Chin failed to meet established medical standards of care. They were found negligent for permitting Varian to have a double mastectomy when she was just 16 years old.

This procedure, which removes both breasts, carries risks such as bleeding and infection. Side effects may include pain, numbness, or limited arm movement, and full recovery can take considerable time.

The three-week trial focused on the medical approach taken by the doctors. Varian’s legal team argued that the medical professionals rushed her toward an irreversible procedure, overlooking several underlying mental health issues. Testimony revealed that at age 16, Varian was battling anorexia, body dysmorphia, depression, ADHD, and was on the autism spectrum.

The jury sided with the plaintiff, believing these mental health conditions should have been thoroughly examined and managed before any surgical decisions were made. They ruled that the defendants had missed crucial steps in the evaluation process.

A pivotal moment in the trial involved Varian’s mother, Claire Deacon, who recounted her initial resistance to the surgery. Under pressure from Dr. Einhorn, she eventually consented, describing how he used “scare tactics” that suggested her daughter was at a high risk of suicide without the surgery, portraying it as vital for her daughter’s happiness.

The defense contended that Varian had independently expressed thoughts of self-harm and argued that the medical team followed guidelines set by the World Professional Association for Transgender Health (WPATH).

Nevertheless, the jury concluded that the doctors did not sufficiently communicate about Varian’s treatment and failed to inform her of all the risks and alternatives associated with the surgery.

In awarding damages, the jury recognized both the physical and emotional challenges Varian faced, as detailed during her testimony.

“It’s so hard to face that you are disfigured for life,” she said. “No amount of reconstruction is ever going to bring back what I lost.”

Varian learned through her experiences that surgery couldn’t alter her sex permanently, but it did result in lifelong scars and complications, including nerve pain and the realization that she will not be able to breastfeed in the future.

Following this verdict, many legal experts suggest that the outcome may have significant implications for pediatric gender medicine. Many similar cases have previously been dismissed or settled due to their association with cultural debates.

What distinguishes the Varian case is its reliance on a traditional medical malpractice approach: it didn’t focus on whether transitioning was “right or wrong,” but rather on the alleged negligence of these specific doctors. This may lead insurers to reconsider coverage and pricing for pediatric gender surgeries to mitigate the risk of costly “detransition” claims.